Tesaro On Track For Mid-Year NDA Filing Of Oral CINV Candidate Rolapitant
This article was originally published in The Pink Sheet Daily
While awaiting data from the third and final Phase III trial of the oral cancer supportive care candidate, Tesaro also will advance an I.V. formulation of rolapitant. Meanwhile, PARP inhibitor niraparib is in two Phase III trials in oncology indications, with a plan to seek other tumor types the compound might treat.
You may also be interested in...
Tesaro Inc. announced the launch of a Phase III trial for its PARP inhibitor niraparib in ovarian cancer, while registrational data from three global Phase III studies for anti-emetic rolapitant are due by the end of 2013.
Tesaro’s three-drug oncology program, including its lead NK-1 product for chemo-induced nausea and vomiting, is boosted by a recent raise from the public markets.
The US agency’s 2021 device funding request for $21m above its 2020 budget will be frozen under a continuing resolution, making planning difficult.